We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.32%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.02B
AUM Growth
+$175M
Cap. Flow
-$2.02B
Cap. Flow %
-40.15%
Top 10 Hldgs %
37.55%
Holding
141
New
17
Increased
15
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$70.1M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$58M
3
RVMD icon
Revolution Medicines
RVMD
+$44M
4
LRMR icon
Larimar Therapeutics
LRMR
+$27.8M
5
VERV
Verve Therapeutics
VERV
+$23.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$98.4M
2
AHCO icon
AdaptHealth
AHCO
+$60.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$59M
4
GKOS icon
Glaukos
GKOS
+$53.6M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
2 Financials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WINT
101
DELISTED
Windtree Therapeutics
WINT
– –
0
– –
BIIB icon
102
CALL
Biogen
BIIB
$29.8B
– –
-500,000
Closed -$102M
ETNB
103
DELISTED
89bio
ETNB
– –
-506,100
Closed -$1.63M
GKOS icon
104
Glaukos
GKOS
$8.84B
– –
-1,039,514
Closed -$53.6M
KZR
105
DELISTED
Kezar Life Sciences
KZR
– –
-141,900
Closed -$11.7M
NKTX icon
106
Nkarta
NKTX
$165M
– –
-600,000
Closed -$7.39M
OM icon
107
Outset Medical
OM
$80.1M
– –
-26,708
Closed -$5.95M
ORGO icon
108
Organogenesis Holdings
ORGO
$332M
– –
-4,447,740
Closed -$21.7M
RYTM icon
109
Rhythm Pharmaceuticals
RYTM
$7.38B
– –
-291,005
Closed -$1.21M
SNDX icon
110
Syndax Pharmaceuticals
SNDX
$1.85B
– –
-1,111,111
Closed -$21.4M
XLO icon
111
Xilio Therapeutics
XLO
$58.2M
– –
-148,478
Closed -$6.07M
MTACU
112
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$0 ﹤0.01%
1
– –
EUCRU
113
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$0 ﹤0.01%
1
– –
SRSAU
114
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$0 ﹤0.01%
1
– –
HZNP
115
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-313,000
Closed -$25M
1 2 3 4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2022 Portfolio in Review

As of Q3 2022, Deerfield Management held 141 positions worth $5.02B, up 3.6% from $4.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $2.02B in Q3 2022, closing 12 positions and reducing 22 holdings. Its most notable exit was Glaukos, an estimated $53.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 51% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Biogen worth $88.1M.

  • Deerfield Management's largest Q3 2022 buy was Biogen: 330,000 shares worth $88.1M.
  • Deerfield Management added most to Revolution Medicines in Q3 2022, an estimated $44M increase.
  • Deerfield Management's biggest Q3 2022 reduction was Viatris, cutting an estimated $98.4M.
  • Deerfield Management fully exited Glaukos in Q3 2022, selling an estimated $53.6M.
  • Deerfield Management's ten largest holdings make up 38% of its $5.02B portfolio in Q3 2022.
  • Deerfield Management opened 17 new positions and closed 12 in Q3 2022.
  • Deerfield Management's portfolio value rose 3.6% quarter-over-quarter to $5.02B.

Based on Deerfield Management's 13F filing for Q3 2022, filed 14 Nov 2022.